Dr. Reddy’s launches generic of Uloric in U.S.

Drugmaker Dr. Reddy’s Laboratories has launched Febuxostat Tablets, a therapeutic equivalent generic version of Uloric (Febuxostat) Tablets, in the U.S. market.

A release from Dr. Reddy’s, citing IQVIA Health numbers, said the Uloric brand and generic had U.S. sales of around $108 million MAT for the 12 months ended October 2020. The product is for the management of hyperuricemia or high uric acid level in adult patients with gout. Uloric is a trademark of Japanese firm Teijin.

The launch by Dr. Reddy’s follows approval from the U.S. Food and Drug Administration (USFDA) and the Febuxostat Tablets are available in 40 mg and 80 mg strengths in bottle count sizes of 30 tablets, the release said.


You have reached your limit for free articles this month.

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Personalised recommendations

A select list of articles that match your interests and tastes.

Faster pages

Move smoothly between articles as our pages load instantly.


A one-stop-shop for seeing the latest updates, and managing your preferences.


We brief you on the latest and most important developments, three times a day.

Support Quality Journalism.

*Our Digital Subscription plans do not currently include the e-paper, crossword and print.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.